Literature DB >> 1666558

Alpha 1-adrenergic system and arrhythmias in ischaemic heart disease.

T Kurz1, K A Yamada, S D DaTorre, P B Corr.   

Abstract

Several lines of experimental evidence obtained over the last decade indicate that alterations in the alpha 1-adrenergic receptor system may contribute significantly to arrhythmogenesis in the ischaemic heart. Under normal physiological conditions, alpha 1-adrenergic stimulation of myocytes elicits a modest increase in inotropy, a lengthening of repolarization secondary to a decrease in IK through activation of protein kinase C, and a decrease in automaticity in Purkinje cells due to an increase in Na+/K+ ATPase activity. These findings suggest that alpha 1-adrenergic stimulation of the myocardium would elicit an antiarrhythmic effect. However, during both early ischaemia and reperfusion there is an enhanced responsivity to alpha-adrenergic stimulation and a potent antiarrhythmic effect of alpha 1-adrenergic blockade in several species including the conscious dog. This enhanced alpha-adrenergic responsivity may be due to an increase in alpha 1-adrenergic receptors in ischaemic myocardium originating from a site distinct from the intracellular site for trafficking of beta-adrenergic receptors, possibly within or near the sarcolemma. Recently, we developed an isolated adult canine ventricular myocyte preparation which also exhibits a 2- to 3-fold reversible increase in alpha 1-adrenergic receptors in response to severe hypoxia (PO2 = less than 15 mmHg) associated with marked sarcolemmal accumulation of long-chain acylcarnitines (LCA) secondary to hypoxia-induced inhibition of beta-oxidation of fatty acids. The increase in alpha 1-adrenergic receptors is prevented by inhibition of carnitine acyltransferase I which precludes accumulation of LCA. The sarcolemmal accumulation of LCA increases membrane fluidity, suggesting that the alpha 1-adrenergic receptor may be latent within or near the sarcolemma and becomes accessible to a surface ligand only as membrane fluidity is altered. This conclusion is also supported by our findings that hypoxia elicits a marked increase in the coupling of the alpha 1-adrenergic receptor to inositol 1,4,5-trisphosphate (IP3) production in canine myocytes exposed to norepinephrine. IP3 has been shown to mobilize Ca2+ from the sarcoplasmic reticulum, thereby modulating the levels of intracellular Ca2+. Stimulation of hypoxic myocytes with norepinephrine also results in the appearance of delayed after-depolarizations and triggered rhythms, probably in response to an increase in intracellular Ca2+. In conclusion, these findings indicate that the alpha 1-adrenergic system can contribute to arrhythmogenesis in the ischaemic heart and that approaches to reduce the incidence of sudden cardiac death should include blockade of alpha 1-adrenergic receptors.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1666558     DOI: 10.1093/eurheartj/12.suppl_f.88

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  13 in total

Review 1.  [Antiarrhythmic therapy with β-receptor antagonists].

Authors:  G C Grönefeld; D Bänsch
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2010-11-24

2.  Inhibition of the alpha(1D)-adrenergic receptor gene by RNA interference (RNAi) in rat vascular smooth muscle cells and its effects on other adrenergic receptors.

Authors:  Bei Sun; Ekaterina Kintsurashvili; Deborah Ona; Ivana Ignjacev-Lazich; Irene Gavras; Haralambos Gavras
Journal:  Vascul Pharmacol       Date:  2007-01-23       Impact factor: 5.773

3.  Alpha blockade potentiates CPVT therapy in calsequestrin-mutant mice.

Authors:  Efrat Kurtzwald-Josefson; Edith Hochhauser; Katia Bogachenko; Shiraz Harun-Khun; Guy Katz; Dan Aravot; Jonathan G Seidman; Christine E Seidman; Michael Eldar; Asher Shainberg; Michael Arad
Journal:  Heart Rhythm       Date:  2014-04-21       Impact factor: 6.343

4.  An experimental model for hypertensive crises emergencies: Long-term high-fat diet followed by acute vasoconstriction stress on spontaneously hypertensive rats.

Authors:  Hong Liu; Wei-Wei Su; Chao-Feng Long; Wei-Jian Zhang; Pei-Bo Li; Zhong Wu; Yin-Yin Liao; Xuan Zeng; Tao-Bin Chen; Yu-Ying Zheng; Zeng-Hao Yan; Cong Bi; Hong-Liang Yao
Journal:  Exp Biol Med (Maywood)       Date:  2018-02-14

Review 5.  Cardiac and neuroprotection regulated by α(1)-adrenergic receptor subtypes.

Authors:  Dianne M Perez; Van A Doze
Journal:  J Recept Signal Transduct Res       Date:  2011-02-21       Impact factor: 2.092

6.  Slc26a6: a cardiac chloride-hydroxyl exchanger and predominant chloride-bicarbonate exchanger of the mouse heart.

Authors:  Bernardo V Alvarez; Dawn M Kieller; Anita L Quon; Daniel Markovich; Joseph R Casey
Journal:  J Physiol       Date:  2004-10-21       Impact factor: 5.182

7.  Possible role of phospholipase C in the induction of Ca(2+)-paradox in rat heart.

Authors:  S Persad; A Vrbanova; J T Meij; V Panagia; N S Dhalla
Journal:  Mol Cell Biochem       Date:  1993-04-21       Impact factor: 3.396

8.  A1 adenosine receptors and muscarinic cholinoceptors in myocardial ischemia.

Authors:  M Ungerer; M Stocker; G Richardt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-06       Impact factor: 3.000

9.  Activation of cardiac human ether-a-go-go related gene potassium currents is regulated by alpha(1A)-adrenoceptors.

Authors:  Dierk Thomas; Kezhong Wu; Anna-Britt Wimmer; Edgar Zitron; Bettina C Hammerling; Sven Kathöfer; Sonja Lueck; Ramona Bloehs; Volker A W Kreye; Johann Kiehn; Hugo A Katus; Wolfgang Schoels; Christoph A Karle
Journal:  J Mol Med (Berl)       Date:  2004-09-08       Impact factor: 4.599

10.  Adrenergic and glucocorticoid receptor antagonists reduce ozone-induced lung injury and inflammation.

Authors:  Andres R Henriquez; Samantha J Snow; Mette C Schladweiler; Colette N Miller; Janice A Dye; Allen D Ledbetter; Judy E Richards; Kevin Mauge-Lewis; Marie A McGee; Urmila P Kodavanti
Journal:  Toxicol Appl Pharmacol       Date:  2017-12-13       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.